2 recruiting, 1 active not recruiting. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Recruiting 2, Active not recruiting 1 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow Jonathan Brammer: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma Ruxolitinib, Positron emission tomography-computed tomography, Bone Marrow Biopsy - T-cell Lymphoma, Graft Versus Host Disease | Phase 2 | Recruiting | Jonathan Brammer | 44 | 2026-02-12 | 2026-04-15 |
| Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia Ruxolitinib - T-Cell Large Granular Lymphocyte Leukemia | Phase 2 | Recruiting | Jonathan Brammer | 30 | 2023-05-03 | 2026-10-01 |
| Oral Azacitidine for the Treatment of Relapsed or Refractory T-cell Large Granular Lymphocytic Leukemia Oral Azacitidine - T-Cell Large Granular Lymphocyte Leukemia | Phase 1 / Phase 2 | Active not recruiting | Jonathan Brammer | 11 | 2022-06-29 | 2026-10-21 |
Leukemia, Large Granular Lymphocytic (2) · Graft vs Host Disease (1) · Leukemia (1) · Leukemia, Prolymphocytic, T-Cell (1) · Lymphoma (1) · Lymphoma, T-Cell (1) · Lymphoma, T-Cell, Cutaneous (1) · Lymphoma, T-Cell, Peripheral (1) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (1)
ruxolitinib (2) · Azacitidine (1) · Biopsy (1) · cc-486 (1)
United States (3)